Fact CheckerSign in

NCT07835854Not yet recruiting

Individualized Exercise Training in Hypertrophic Cardiomyopathy

Graded Exercise Training For Individualized Treatment in Hypertrophic Cardiomyopathy: GET-FIT Hypertrophic Cardiomyopathy Study

Source: ClinicalTrials.gov · Last updated 23 Sept 2026

Brief summary (registry, in English)

Exercise intervention trials in patients with hypertrophic cardiomyopathy (HCM) have demonstrated an association with improvement in resting and exercise hemodynamics, ventricular remodeling, and anxiety/depression. However, no randomized controlled trials (RCTs) to date have assessed the effects of exercise intervention in patients with HCM on cardiac myosin inhibitors (CMIs). This trial aims to evaluate the efficacy of a 12-week individualized exercise training program in HCM patients receiving aficamten.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
60 (estimated)
First submitted
17 Sept 2026
Start date
15 Sept 2026
Primary completion date
30 Jul 2028
Lead sponsor
Oregon Health and Science University
NCT number
NCT07835854

What you commit to

  • Study type: Interventional
  • Planned participants: 60
  • From 15 Sept 2026 to the primary completion date, 30 Jul 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Sustained ventricular arrhythmias or ICD shock within 6 months.
  • Recent acute coronary syndrome or coronary artery bypass \< 6 months.
  • Recent cardiac medication changes for management of cardiomyopathy.

Other

  • Residual left ventricular outflow tract obstruction (peak gradient ≥50mmHg at rest).
  • Pregnancy.
  • Severe valvular stenosis.
  • Large pericardial effusion.
  • Recent acute myocarditis (\< 3 months).
  • Patients with investigational intracardiac devices.

Who the study is looking for

  • Age 18-80 years.
  • Clinical diagnosis of HCM.
  • Able to perform endurance and resistance exercise.
  • Currently on stable dose of aficamten
  • Not meeting current guideline recommended physical activity recommendations (150-300 minutes of moderate-vigorous physical activity/week, strength training ≥2 times weekly).
  • Adequate clinical stability has been achieved (in the judgment of the investigator) to allow participation in study assessments and intervention.
  • Signed informed consent indicating that the patient understands the purpose of the study, the procedures required and is willing to participate.

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.